We performed a systematic review of randomized controlled trials to determine whether the use of dexamethasone therapy in the first 15 days of life is beneficial for prevention of chronic lung disease in prematurely born infants. Studies were identified by conducting a literature search using the Me
Strategy for the prevention and treatment of chronic lung disease of the premature infant
β Scribed by Yunosuke Ogawa; Hiroshi Shimizu; Jiro Takasaki; Toshihiko Nakamura
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 475 KB
- Volume
- 27
- Category
- Article
- ISSN
- 8755-6863
No coin nor oath required. For personal study only.
β¦ Synopsis
Based on the analyses of approximately 1,000 infants with CLD, this condition was classified into 7 types according to the preceding illnesses and the chest X-ray appearance. The profile of inflammatory enzymes, cytokines and chemical mediators supported the relevance of the classification. Since different insults to the lung with different onsets exhibit the different spectra of the disease, appropriate strategies adapted to each type of CLD should be pursued. For types I and II prophylactic administration of exogenous surfactant, early enough to prevent the oxygen toxicity and barotrauma, is important. RDS can be diagnosed by the stable microbubble rating on gastric aspirates within several minutes of birth. The application of milder modes of ventilation such as HFOV started at birth should also be remembered. The recommended strategies for type IV and V are the care of the very low birth weight infant in the fully humidified incubator with careful fluid administration to prevent symptomatic PDA, and early detection and treatment of infection by screening with sensitive methods such as the APR score. However, the most difficult problem is to identify the correct strategy for type III and III', because these types of CLD can only be prevented by the complete eradication of intrauterine infection.
π SIMILAR VOLUMES
Gene therapy, which is the deliberate transfer of DNA for therapeutic purposes, can be defined as the in situ production of a therapeutical material within the diseased cells. The eye is an ideal target for gene therapy, as it is confined to a small space, separated by the retina-blood barrier from
An increased understanding of the biology of prostate carcinoma has led to the clinical evaluation of mechanism-based and targeted therapies. Modulating the immune system has been pursued through the use of both active and passive immunity as well as the ex vivo genetic manipulation of effector cell